- Home
- CFND vs COEP Comparison
CFND vs COEP Comparison
Compare CFND & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CFND | COEP |
|---|---|---|
| Founded | N/A | 2017 |
| Country | | United States |
| Employees | N/A | 7 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.4M | 72.7M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | CFND | COEP |
|---|---|---|
| Price | $3.93 | $12.04 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 22.7K | ★ 32.8K |
| Earning Date | N/A | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.68 | $6.32 |
| 52 Week High | $9.67 | $21.41 |
Technical Indicators
Market Signals| Indicator | CFND | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 43.21 | 45.69 |
| Support Level | $3.75 | $10.98 |
| Resistance Level | $4.08 | $13.23 |
| Average True Range (ATR) | 0.18 | 0.94 |
| MACD | 0.03 | 0.08 |
| Stochastic Oscillator | 40.28 | 41.06 |
Price Performance
Historical ComparisonAbout CFND C1 Fund Inc.
C1 Fund Inc is a non-diversified, closed-end management investment company designed to give investors access to the private digital asset ecosystem. Its investment objective is to maximize its portfolio's total return. The fund targets a handpicked portfolio of the late-stage private companies driving the future of digital asset services and technology. It offers early access to the next generation of category-defining companies and aims to bridge the gap between public and private markets and give investors access to the private companies with the safeguards of a NYSE listed fund that is regulated and liquid.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.